Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2003
04/24/2003CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003CA2459572A1 Composition comprising a lactobacillus pentosus strain and uses thereof
04/24/2003CA2458981A1 Combinations comprising cox-2 inhibitors and aspirin
04/23/2003EP1304346A2 Conjugate of polyethylene glycol and chitosan
04/23/2003EP1304327A2 Glutamine-thiazolidide and -pyrrolidide and their use as dipeptidylpeptidase IV inhibitors
04/23/2003EP1304123A2 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
04/23/2003EP1304121A1 Body weight gain inhibitors
04/23/2003EP1304111A2 Use of methylol-containing compounds for the treatment of breast cancer
04/23/2003EP1304048A1 Composition to reduce or quit smoking addiction
04/23/2003EP1303631A2 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes
04/23/2003EP1303625A2 Alpha-msh related compounds and methods of use
04/23/2003EP1303620A2 Regulation of human desc1-like serine protease
04/23/2003EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction
04/23/2003EP1303596A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
04/23/2003EP1303591A2 Masp-2, a complement-fixing enzyme, and uses for it
04/23/2003EP1303541A1 Gel compositions containing metronidazole
04/23/2003EP1303540A2 Multi-specific reagent for selective stimulation of cell surface receptors
04/23/2003EP1303537A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases
04/23/2003EP1303536A1 Novel fibroblast growth factor (fgf23) and methods for use
04/23/2003EP1303515A2 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
04/23/2003EP1303513A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
04/23/2003EP1303488A1 Piperidine compounds for use as ccr-3 inhibitors
04/23/2003EP1303487A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
04/23/2003EP1303310A1 USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS
04/23/2003EP1303308A2 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
04/23/2003EP1303307A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
04/23/2003EP1303306A2 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
04/23/2003EP1303305A2 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
04/23/2003EP1303304A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
04/23/2003EP1303301A2 Preventing airway mucus production by administration of egf-r antagonists
04/23/2003EP1303294A2 Method for treating unstable angina pectoris
04/23/2003EP1303293A2 Apo-2l receptor agonist and cpt-11 synergism
04/23/2003EP1303290A1 Small peptides and methods for downregulation of ige
04/23/2003EP1303285A2 Methods and formulations with probiotic microorganisms and medicaments
04/23/2003EP1303279A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
04/23/2003EP1303278A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
04/23/2003EP1303271A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
04/23/2003EP1303265A2 Use of cox-2 inhibitors for preventing immunodeficiency
04/23/2003EP1303264A1 Compositions and methods for treating cardiovascular disorders
04/23/2003EP1303262A2 Use of a spla2 inhibitor for the treatment of sepsis
04/23/2003EP1303261A2 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
04/23/2003EP1303192A1 Dietary lipids for improving skin and coat of pets
04/23/2003EP1242009A4 Tissue sensitizing compounds for females with methods and apparatus for the delivery of these compounds
04/23/2003EP1185257A4 Treatment of acne using lipoic acid
04/23/2003EP1178820A4 Methods of modulating fabh activity
04/23/2003EP1154794B1 Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
04/23/2003EP1121102B1 Liposome-entrapped topoisomerase inhibitors
04/23/2003EP1107744B1 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
04/23/2003EP1082314B1 New dipeptidyl peptidase iv effectors
04/23/2003EP1057033B1 Treating cancer
04/23/2003EP1057032B1 Treating cancer
04/23/2003EP1057031B1 Treating cancer
04/23/2003EP1057030B1 Treating cancer
04/23/2003EP1057029B1 Treating cancer
04/23/2003EP1057028B1 Treating cancer
04/23/2003EP1017363B1 Taste masking for unpalatable formulations
04/23/2003EP0956022B1 Hormonal composition consisting of an oestrogen compound and of a progestational compound
04/23/2003EP0764021B1 Uterine fibroid treatment
04/23/2003EP0672145B1 Interleukin-3 (il-3) multiple mutation polypeptides
04/23/2003CN1413230A Highly-neutralized ethylene copolymers and their use in golf balls
04/23/2003CN1413220A Anti-prostate stem cell antigen (PSCA) antibody compositions and method of use
04/23/2003CN1413207A 5-membered ring heterocyclic compounds with nitrogen
04/23/2003CN1413197A 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
04/23/2003CN1413190A EP4 receptor selective agonists in treatment of osteoporosis
04/23/2003CN1413186A Aminobenzophenones as inhibitors of IL-1 beta and TNF-alpha
04/23/2003CN1413113A Method of treating gastrointestinal tract disease using purinergic receptor agonists
04/23/2003CN1413111A Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
04/23/2003CN1413110A Pharmaceutical composition
04/23/2003CN1413107A Use of hypoglycemic agent for treating impaired clucose metabolism
04/23/2003CN1413100A Local prevention or amelioration of pain from surgically closed wounds
04/23/2003CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions
04/22/2003US6552216 Molecular model for VLA-4 inhibitors
04/22/2003US6552167 Chemically modifying target molecules, e. g. macromolecules, particularly biologically important polypeptides, and surfaces (e.g., gold or glass) by means of covalent attachment of polyamide chains of precise length
04/22/2003US6552077 Kidney disorders
04/22/2003US6552074 Arginine/ascorbic acid mixed powder as an oral supplement
04/22/2003US6552066 Protein tyrosine kinase inhibitors for treating osteoarthritis
04/22/2003US6552055 Methods and pharmaceutical compositions for inhibiting tumor cell growth
04/22/2003US6552047 H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
04/22/2003US6552045 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
04/22/2003US6552031 Synergistic analgesic combination of oxycodone and rofecoxib
04/22/2003US6552020 Compositions including antibiotics and methods for using same
04/22/2003US6552010 Treatment of SLE with dehydroepiandrosterone
04/22/2003US6552009 Compositions and methods of treating abnormal cell proliferation
04/22/2003US6552006 Treating intracellular parasitic infection in humans; administer to human immunomodulatory nucleic acid and parasitide, monitor humans response, decrease in parasite replication indicates infection preventative
04/22/2003US6551993 Administering partial glycine agonist to the glycine modulatory site of the NMDA receptor complex of mammals for therapy of cognitive dysfunction such as inattention
04/22/2003US6551989 Preventing airway mucus production by administration of EGF-R antagonists
04/22/2003US6551823 EBV-infected stomach cancer cell line
04/22/2003US6551822 NL4 tie ligand homologue
04/22/2003US6551812 Diagnosing PPAR pathophysiologies, and identifying agents for treating these pathophysiologies, using nucleic acids whose expression changes following addition to cells of a ligand for PPAR
04/22/2003US6551811 Protein comprises at least one site for N-linked glycosylation and is attached to a plasma membrane by a glycosylphosphatidylinositol radical
04/22/2003US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase
04/22/2003US6551792 Nucleotide sequence which encodes a flavin monooxygenase, the corresponding protein and their uses in the spheres of diagnosis and therapy
04/22/2003US6551785 Determining a subject's susceptibility to or the rapidity of progression of sepsis in a subject by detecting at least one allele of an Interleukin-1 proinflammatory haplotype in a nucleic acid sample which indicates increased susceptibility
04/22/2003US6551626 Composition containing pyrrolizidine-alkaloid-free petasites
04/22/2003US6551623 Immunomodulating compositions from bile
04/22/2003US6551617 Taste masking coating composition
04/22/2003US6551607 Method for sequestration of skin irritants with substrate compositions
04/22/2003US6550482 Methods for non-permanent occlusion of a uterine artery
04/22/2003CA2222713C Composition comprising d-threo-methylphenidate and another drug
04/22/2003CA2102623C Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
1 ... 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 ... 1151